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Abstract
 HELLP syndrome, characterized by he-
molysis, elevated liver enzymes, and low platelets, 
is one of the diseases related to hypertension in 
pregnancy. If the pregnancy is not terminated 
soon after HELLP is diagnosed, liver failure or 
disseminated intravascular coagulopathy (DIC) 
may occur. HELLP syndrome occurs in 0.2%–
0.9% of all pregnancies; Onset before 24 weeks 
of gestation is extremely rare but is more likely to 
result in stillbirth. Women who have had a still-
birth often hope for another pregnancy soon after, 
but there is little information about the risks and 
outcomes for subsequent pregnancy in women who 
developed HELLP syndrome in early pregnancy. 
Thus, it is important to accumulate data on these 
outcomes in this population. Here, we report a case 
in which severe HELLP syndrome developed at 22 
weeks of gestation, resulting in stillbirth, and was 
followed six months later by a pregnancy that with 
early intervention, produced a live birth.
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Introduction
    
 HELLP syndrome, diagnosed on the basis 
of hemolysis, liver dysfunction, and thrombocyto-
penia, generally occurs (80%–90% of cases) in the 
context of hypertension, proteinuria, and edema—
the identifying features of maternal hypertensive 
disorder 1. HELLP syndrome can be fatal as a re-
sult of progression to liver failure and disseminated 
intravascular coagulopathy (DIC), if diagnosis is 
delayed. Maternal mortality resulting from HELLP 
has been reported to be in the range of 2%–24% 1. 
HELLP syndrome occurs in 0.2%–0.9% of all 
pregnancies. Approximately 10% of cases occur at 
24–26 weeks, 70% at 27–37 weeks, and 20% after 
38 weeks of gestation 2; onset before 24 weeks is 
very rare. 
 A study that followed women with a his-
tory of HELLP syndrome reported that in the next 
pregnancy, HELLP syndrome recurred in 13% and 
preeclampsia occurred in 16% of cases 3; however, 
it is unclear whether HELLP syndrome (or other 
pregnancy complications) are more likely in preg-
nancies following HELLP syndrome that occurred 
very early in pregnancy. 
 Here, we report a case in which severe 
HELLP syndrome developed at 22 weeks, resulting 
in stillbirth, and was followed six months later by a 
pregnancy that produced a term birth.
Case presentation
 The patient was a 27-year-old primipara 
with no prior pregnancies. The patient had been 
treated for asthma in childhood but had not re-
quired treatment as an adult; her family history 
was unremarkable. The patient was naturally preg-
nant and had routine medical examinations prior 
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to the event. At 18 weeks of gestation, leg edema 
appeared, but her blood pressure was within nor-
mal limits, and there was no proteinuria. At 22 
weeks and 1 day of gestation, the patient presented 
to clinic complaining of epigastric pain for 3 days. 
An abdominal ultrasonography showed no major 
abnormality, and the patient was decided that there 
was no need for hospitalization. On the following 
day, at 22 weeks and 2 days of gestation, the patient 
returned with increased epigastric pain and was 
promptly admitted to hospital for severe general-
ized edema, headache and epigastric pain, elevat-
ed blood pressure (now 144/99 mmHg), and gross 
hematuria. At this time, blood tests from the pre-
vious day were found to be abnormal, with aspar-
tate transaminase (AST) 107 U/L, alanine amino-
transferase (ALT) 126 U/L, lactate dehydrogenase 
(LDH) 339 IU/L, and platelets 60,000 /μL (Table 
1). On transabdominal ultrasonography: uterine 
artery Doppler revealed notches in the blood flow 
waveform (Fig. 1); the fetus showed asymmetri-
cal growth restriction, with estimated weight 431 
Table 1.    Laboratory results at admission.
Result Normal range
WBC (/μL) 8,400 3,300–8,600
Hb (g/dL) 10.7 11.6–14.8
PLT (x10,000/μL) 6.0 15.8–34.8
AST (U/L) 107 13–30
ALT (U/L) 126 7–23
LDH (IU/L) 339 124–222
T Bil (mg/dL) 0.9 0.4–1.5
Cr (mg/dL) 0.57 0.46–0.79
BUN (mg/dL) 13 8–20
CRP (mg/dL) 2.601 0.0–0.9
Abbreviations: WBC, white blood cell; Hb, hemoglobin; PLT, platelets; AST, aspartate transaminase; 
ALT, alanine aminotransferase; LDH, lactate dehydrogenase; T Bil, total bilirubin; Cr, creatinine; BUN, 
blood urea nitrogen; CRP, c-reactive protein
Figure 1.   Blood flow in the uterine artery. 
Notches were found in the uterine artery blood flow waveform.
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g (−1.5 standard deviation [SD]); fetal movement 
was poor, and the amniotic fluid index was 10.7 
cm.
 The patient was diagnosed with HELLP 
syndrome, and treatment was initiated with 
nicardipine hydrochloride (1 mg/h) to lower blood 
pressure and magnesium sulfate hydrate (1 g/h) to 
prevent vasospasm and eclampsia. Twenty units of 
platelets were transfused but despite this, the pa-
tient’s clinical condition rapidly deteriorated (lab-
oratory data are shown in Fig. 2). Pregnancy was 
deemed to be life-threatening, and an emergency 
cesarean section was performed under general 
anesthesia. A male infant (360 g) was delivered 
through a longitudinal midline incision. A large 
amount of serous ascites was observed in the ab-
dominal cavity. Apgar scores were 1 at 1 min and 1 
at 5 min (heart rate less than 100) and resuscitation 
was done, but failed to respond and he was deemed 
stillborn.
 The platelet count had increased to 72,000 
/µL following transfusion on the day of the cesar-
ean section but then decreased to 37,000 /µL on 
postoperative day (POD) 1, requiring a further 
transfusion of 15 units of platelets. Blood pressure 
was controlled with oral nifedipine (20 mg/day). 
Liver enzymes gradually decreased and normalized 
on POD 8. Urine protein was 5.68 g/day on POD 3 
but decreased to 1.32 g/day by POD 12. On POD 
14, the patient was discharged. By POD 20, urinary 
protein had fallen below 300 mg/day. On POD 36, 
urine protein was 40 mg/day and blood pressure 
was 117/78 mmHg.
 At 197 days after the cesarean section, the 
patient presented following a positive pregnancy 
test, reportedly 5 weeks after her last menstrual 
period. Ultrasound confirmed an intrauterine ges-
tational sac consistent with 5 weeks of gestation. 
Figure 2.    Changes in the laboratory values. 
(A) AST/ALT/LDH　(B) Hb/PLT　(C) aPTT/AT III/PT-INR　(D) Cr / Urine TP 
Abbreviations: AST, aspartate transaminase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; Hb, hemo-
globin; PLT, platelets; aPTT, activated partial thromboplastin time; AT III, antithrombin III; PT, prothrombin time; 
INR, international normalized ratio; Cr,creatinine; TP, total protein; C/S, cesarean section; POD, postoperative day.
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Blood tests were negative for antiphospholipid 
antibodies, anti–β2 glycoprotein 1 antibodies, and 
antinuclear antibodies, and showed no evidence of 
antiphospholipid antibody syndrome or other au-
toimmune disorders or abnormal coagulation. Her 
blood pressure was within normal range, but home 
blood pressure measurement was ordered because 
she had hypertension during her last pregnancy and 
was considered to be at high risk this time as well. 
Oral acetylsalicylic acid, 81 mg/day, was com-
menced (and continued until 28 weeks) in the hope 
of suppressing platelet function and preventing hy-
pertensive disease. At 10 weeks of gestation, the pa-
tient presented with blood pressure 146/87 mmHg. 
Home blood pressure was within normal limits, 
but the systolic blood pressure was close to 140 
mmHg, therefore, oral hydralazine hydrochloride, 
20 mg/day, was started. At 28 weeks, ultrasound 
estimated the fetal weight to be −1.6 SD, prompt-
ing the diagnosis of fetal growth restriction. There 
were no other fetal abnormalities. At 31 weeks, the 
estimated weight of the fetus was −1.7 SD, and at 
31 weeks and 4 days the patient was hospitalized 
to observe the condition of the fetus closely. Fol-
lowing admission, her blood pressure remained 
stable on oral hydralazine hydrochloride, 20 mg/
day, at roughly 110/70 mmHg, and her urine was 
free of protein. The estimated fetal weight contin-
ued to be low but increased, ranging from −1.3 SD 
to −1.7SD, and nonstress tests were in the normal 
range. An elective cesarean section was performed 
at 37 weeks and 5 days, as indicated by a previous 
cesarean section. The female infant weighed 2,276 
g (small for gestational age) and had Apgar scores 
of 8 and 9 at 1 min and 5 min, respectively. The 
mother and child were both well and discharged on 
POD 8. Ten years later, the patent is normotensive 
and is not on any medication. The child is also in 
good health.
Discussion
 We treated a rare condition—HELLP syn-
drome at 22 weeks of gestation. HELLP syndrome 
can be severe, escalating to hepatic failure and DIC 
and requiring pregnancy termination without delay. 
In our reported case, LDH was not so high, and nei-
ther Tennessee classification 4 nor Mississippi-tri-
ple class system 5 was met, but it was predicted that 
the condition would rapidly worsen from the symp-
toms, high AST / ALT, and low platelets, and it was 
managed as HELLP syndrome. Total Bilirubin was 
normal, and haptoglobin or peripheral blood pic-
ture was not examined. The most important dif-
ferential diagnosis for HELLP syndrome is acute 
fatty liver of pregnancy (AFLP). However, the 
distinction between HELLP syndrome and AFLP 
is not easy due to the similarity of symptoms and 
blood test findings 6. The pathology of AFLP was 
hepatic insufficiency, and the absence of signifi-
cant thrombocytopenia, hyperbilirubinemia, pro-
longed prothrombin time, and extreme decrease in 
antithrombin III activity were not consistent with 
the present case and was excluded. Gastrointestinal 
disease was also a differential diagnosis based on 
symptoms, but this was ruled out due to changes in 
blood test data and ultrasound findings. Epigastric 
pain and rapid elevation of liver enzymes were not 
typical of hemolytic or autoimmune diseases, and 
these were also excluded.
 Previously, corticosteroid administration 
was reported to extend gestational age 7. However, 
the effect of extending gestational age by cortico-
steroid administration has been denied 8,9. The cur-
rent recommendation is to terminate the pregnancy 
as soon as possible after 34 weeks of gestation; 
prior to 34 weeks, corticosteroid administration is 
recommended to promote infant maturation, with 
pregnancy termination 48 hours later 2,10. If the cer-
vix is mature and induction of delivery is expected, 
vaginal delivery may be considered, but cesarean 
section is often performed for preterm delivery. In 
our reported case, as shown in Fig. 2, the patient’s 
condition rapidly deteriorated, so there was no 
time to administrate corticosteroid and wait for 48 
hours. It was not clear whether the cause of still-
birth is due to the rapid progression of HELLP syn-
drome or the immaturity of the infant.
 While it has been suggested that HELLP 
syndrome is likely to occur as a complication of 
autoimmune diseases, such as antiphospholipid 
antibody syndrome 11, the factors influencing the 
development of HELLP and the risk of recurrence 
in a subsequent pregnancy are unclear—certainly, 
in the present case, autoimmune disease was not 
present. Further, it has been reported that just 1.5% 
of HELLP syndrome cases occur prior to 24 weeks 
of gestation 12; indeed, a recent PubMed search of 
HELLP syndrome before 24 weeks of gestation 
(using the terms “HELLP syndrome” and “second 
trimester pregnancy”) yielded only 11 case reports. 
A retrospective cohort study previously reported 
a stillbirth rate of 9% and perinatal mortality rate 
of 20% in HELLP syndrome cases 13. The authors 
could find no reports summarizing perinatal mor-
tality in HELLP syndrome occurring prior to 24 
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weeks of gestation, but this is likely to be much 
worse—indeed, among the 11 reported cases of 
HELLP syndrome before 24 weeks of gestation, 
there was only one live birth 14. 
 An international cohort study has reported 
a good prognosis for pregnancy within 12 months 
following stillbirth 15; however, there have been 
no reports of outcomes for pregnancies following 
stillbirth in the context of HELLP syndrome. In our 
reported case, hypertension occurred from the ear-
ly stage of pregnancy and was managed as chronic 
hypertension. At birth, the infant weight was low 
(2,276 g at 37 weeks of gestation); however, at 10-
year follow-up, the mother was normotensive with-
out medication, and the child was in good health. 
Unfortunately, HELLP syndrome that develops in 
early second trimester is more likely to result in 
worse prognosis. Women who have experienced 
stillbirth often hope to have another pregnancy 
very soon after, but there is a great deal of anxi-
ety about the course of the next pregnancy. It is 
important to accumulate reports on the outcome of 
pregnancies following stillbirth due to HELLP syn-
drome in order to provide more accurate prognoses 
to patients and their families. Moreover, in the case 
of subsequent pregnancy, the prognosis may be im-
proved by taking measures such as increased med-
ical examinations and management at specialized 
hospitals.
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